Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
Animals
Drug Screening Assays, Antitumor
Fusion Proteins, bcr-abl
/ antagonists & inhibitors
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Mice
Mice, Inbred BALB C
Neoplasms, Experimental
/ drug therapy
Neoplastic Stem Cells
/ enzymology
Protein Kinase Inhibitors
/ pharmacology
Journal
Experimental hematology
ISSN: 1873-2399
Titre abrégé: Exp Hematol
Pays: Netherlands
ID NLM: 0402313
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
09
08
2020
revised:
03
09
2020
accepted:
03
09
2020
pubmed:
11
9
2020
medline:
15
1
2021
entrez:
10
9
2020
Statut:
ppublish
Résumé
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder caused by constitutively active BCR-ABL1 tyrosine kinase resulting from the t(9;22) Philadelphia translocation. Imatinib, a BCR-ABL1 tyrosine kinase inhibitor (TKI), is a revolutionary molecular target inhibitor for CML. However, leukemic stem cells (LSCs) eventually become resistant to imatinib and thereby cause relapse. The next-generation BCR-ABL1 TKI dasatinib is also unable to eliminate CML LSCs. On the other hand, the third-generation BCR-ABL1 TKI ponatinib is not well studied in terms of its efficacy on CML LSCs. Here, we evaluate the efficacy of ponatinib against CML LSC-containing lin
Identifiants
pubmed: 32910995
pii: S0301-472X(20)30548-8
doi: 10.1016/j.exphem.2020.09.186
pii:
doi:
Substances chimiques
BCR-ABL1 fusion protein, human
0
Protein Kinase Inhibitors
0
Fusion Proteins, bcr-abl
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
46-51.e2Informations de copyright
Copyright © 2020 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.